Clinical trial Recruiting at 1 site Observational Ages 18 to 100

New CAR-macrophages tested on patient-derived breast cancer organoids

Official title: Cohort Study to Determine the Antitumor Activity of New CAR-macrophages in Breast Cancer Patients' Derived Organoids (CARMA)

Run by Centre Oscar Lambret · NCT05007379 · Data updated 2026-11-12

This project will test whether newly developed CAR-macrophages can kill breast cancer cells grown in organoids made from patients' own tumor samples.

More Breast Cancer trials

Quick facts

Study typeObservational
Ages18 Years to 100 Years
SexAll
Enrollment100 (estimated)
SponsorCentre Oscar Lambret
Academic / other
Locations1 site (Lille)
StatusRecruiting
StartedNovember 2, 2021
Main results expectedSeptember 1, 2023
Study endsDecember 1, 2027
Registry record updatedMarch 18, 2026
Trial IDNCT05007379 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults (18+) with histologically confirmed breast cancer of any stage who are scheduled for surgery or diagnostic tumor biopsy and who consent to donate tissue and blood are ideal candidates.

Probably not a fit

Patients who refuse biospecimen collection, whose tumors cannot be grown as organoids, or those seeking direct immediate treatment benefit are unlikely to receive personal therapeutic benefit from participation.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational cohort collects tumor tissue and blood from adults with confirmed breast cancer who are undergoing surgery or biopsy. Tumor samples will be used to grow patient-derived organoids, three-dimensional tumor models that preserve features of each patient's cancer. Researchers will apply newly developed CAR-macrophages to these organoids to see whether the modified immune cells reduce tumor growth. Blood samples will be analyzed to characterize each patient's inflammatory status and to explore links between host factors and organoid responses.

Why it matters

Potential benefit: If successful, this work could help identify CAR-macrophage approaches that more effectively kill individual patients' tumor cells and guide the development of personalized therapies.

How similar studies have gone: Preclinical studies using CAR-macrophages and patient-derived organoids have shown promising antitumor activity, but clinical evidence remains limited.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Male or female aged 18 years or more
* Histologically confirmed breast cancer at any stage
* Requiring surgery or tumor biopsy as standard of care
* Any or no systemic treatment
* Signed informaed consent
* Health insurance coverage

Exclusion Criteria:

* Opposed to biospecimen collection

Where it's running

  • Oscar Lambret Center
    Lille, France
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.